PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis.
Stefan SiebertFrank BehrensEnnio LubranoNicolas MartinMohamed SharafChristine ContréElke TheanderRubén QueiroMiriam ZimmermannLaure GossecPublished in: Rheumatology and therapy (2022)
ClinicalTrials.gov identifier: NCT05049798.
Keyphrases